Should I Buy PCRX? PCRX 2026 Analysis

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

24.820

1 Day change

0.42%

52 Week Range

27.640

Analysis Updated At

2026/04/17

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Pacira Biosciences Inc (PCRX) is not a strong buy for a beginner, long-term investor at this moment. While the stock shows some positive technical indicators and hedge fund buying activity, the lack of significant positive catalysts, weak financial performance in the latest quarter, and mixed analyst sentiment suggest a cautious approach. The stock may be better suited for monitoring rather than immediate investment.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 61.767, and moving averages are converging, which suggests no strong directional trend. The stock is trading near its resistance level (R1: 24.15), with support at S1: 22.304. Overall, the technical indicators are moderately positive but not strongly compelling.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are significantly increasing their positions, with a 695.83% increase in buying activity over the last quarter. Analysts highlight the potential cost savings and reduced opioid usage from the company's Exparel product in certain procedures, which could support long-term growth.

Neutral/Negative Catalysts

The company's Q4 financial performance showed a significant decline in net income (-89.79% YoY) and EPS (-88.57% YoY), despite a modest revenue increase. Analyst sentiment is mixed, with one firm lowering its price target and expressing concerns about limited near-term momentum. No recent news or congress trading data to act as a catalyst.

Financial Performance

In Q4 2025, revenue increased by 5.14% YoY to $196.87M, but net income dropped by 89.79% YoY to $1.64M. EPS also declined by 88.57% YoY to $0.04. Gross margin improved slightly to 72.26%, up 1.70% YoY. Overall, financial performance is weak, with declining profitability overshadowing modest revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating with a $38 price target, citing positive real-world data on Exparel. However, Barclays lowered its price target from $27 to $25, maintaining an Equal Weight rating and expressing concerns about limited near-term momentum. Analyst sentiment is mixed, with long-term potential but short-term challenges.

6 Analyst Rating

Wall Street analysts forecast PCRX stock price to rise

4 Buy

1 Hold

1 Sell

Moderate Buy

Current: 24.720

Low

Averages

30.33

High

Current: 24.720

Low

Averages

30.33

High

H.C. Wainwright

Buy

maintain

$38

AI Analysis

2026-04-13

Reason

H.C. Wainwright

Price Target

$38

AI Analysis

2026-04-13

maintain

Buy

Reason

H.C. Wainwright says the real-world data on Exparel indicate it can lead to lower or comparable total healthcare costs and reduced opioid usage. Pacira presented real-world data supporting the payer value proposition of liposomal bupivacaine, the analyst tells investors in a research note. The firm believes the strength of the evidence appears to depend on the specific procedure, with a more compelling economic signal observed in total hip arthroplasty compared to total knee arthroplasty. While the data in total hip arthroplasty pointed to meaningful cost savings, the total knee arthroplasty data points to cost parity, though that doesn't fully capture clinical benefits or patient satisfaction benefits that use of Exparel may provide, contends H.C. Wainwright. The firm believes the data highlights a reduction in opioid usage at six months post-surgery among patients with low back pain who underwent total hip arthroplasty. It keeps a Buy rating on Pacira with a $38 price target. The stock in midday trading is up 1% to $24.11.

Barclays

Equal Weight

downgrade

$27 -> $25

2026-03-26

Reason

Barclays

Price Target

$27 -> $25

2026-03-26

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on Pacira to $25 from $27 and keeps an Equal Weight rating on the shares. The firm left the company's Q4 report "encouraged" by its efforts to drive core revenue acceleration while investing in the pipeline. Pacira's pipeline updates are back half of the year weighted, which could limit near-term positive momentum in the shares, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCRX

Unlock Now

PCRX Should I Buy

PCRX Should I Buy

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch